<DOC>
	<DOCNO>NCT00671528</DOCNO>
	<brief_summary>This parallel-group , randomize , active-controlled , double-blind , Phase 4 trial compare three cream treatment impetiginous eczema : - Arm A : QUADRIDERME® cream ( betamethasone diproprionate , clotrimazole , gentamicin sulfate ) - Arm B : Combination betamethasone diproprionate cream gentamicin sulfate cream - Arm C : Betamethasone diproprionate cream At 7 site , Portugal , total 207 subject randomize use 1:1:1 randomization ratio receive one three possible treatment maximum period 28 day 5 day total remission sign symptom , never 28 day . Assessments make level improvement target area treatment group , number day total remission , safety profile . Note : This study terminate early due lack recruitment ( 3 207 planned participant enrol ) . Statistical analysis perform . Further , 7 site plan , 4 site approve 3 site initiate .</brief_summary>
	<brief_title>Safety Efficacy Quadriderme® Treatment Impetiginous Eczema ( Study P05134AM4 )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Skin Diseases , Eczematous</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>Minimum age : 12 year Good general health confirm clinical history physical skin examination ( exclude area skin impetiginous eczema ) . Diagnosis impetiginous eczema . Ability understand procedure protocol follow requirement course study . Results routine laboratory test hemogram leukogram platelet count , creatinine , glucose , sed . rate , IgE level transaminase ; along plasma cortisol adrenocorticotropic hormone ( ACTH ) level prior start treatment . These result must within normal limit clinically relevant order include trial . Pregnant participant woman childbearing age use birth control method consider reliable attend physician . Participants history hypersensitivity component medication study . Participants extent severity lesion require treatment different type plan trial . Participants need type topical systemic medication trial might affect course disease . Participants treat topical medication 14day period prior start trial . Participants receive systemic corticosteroid immunosuppressant medication 28day period prior start study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Impetiginous</keyword>
</DOC>